In patients with a chronic renal disease at the terminal stage, extrarenal epuration is essential for the control of clinico-biological complications. Two extrarenal epuration techniques are currently available: peritoneal dialysis (using the peritoneal membrane of the patient) and hemodialysis, requiring the use of an external biocompatible membrane known as 'dialysis filter'. This technique requires a vascular access (arteriovenous fistula or dialysis catheter). The thrombosis of vascular accesses represents a major cause of morbidity and mortality in hemodialysis patients. Thrombosis are more frequent when using synthetic prosthetic arteriovenous fistula instead of native arteriovenous fistula. Antiphospholipid Syndrome (APLS) is a rare autoimmune disease characterized by arterial thrombosis, venous thrombosis and obstetrical complications such as as defined by the Sidney's criteria. In the general population, the presence of antiphospholipid antibodies is associated with an increased risk of thromboembolic events. In the nephrological population, this prevalence is higher in hemodialysis patients compared to patients on peritoneal dialysis or non-dialyzed patients. Up to 37% of hemodialysis patients are positive for antiphospholipid antibodies and this biology is associated with thrombotic events and vascular access thromboses. However, some studies do not report this association and there is currently no consensus in terms of the therapeutic management of these patients. Some factors influencing the positivity for antiphospholipid antibodies have been reported: smoking, age, the presence of a non-glomerular nephropathy, hypoalbuminaemia, the use of a central venous catheter for dialysis or the use of a non-biocompatible dialysis membrane. Taking into account the conflicting data from the literature, it seems important to study the respective role(s) of 3 types of antiphospholipid antibodies in the occurrence of thrombo- embolic events in patients undergoing dialysis within the CHU Brugmann Hospital.
Name: Data extraction from medical files
Description: Prevalence of antiphospholipid antibodies
Measure: Prevalence of antiphospholipid antibodies Time: 19 yearsDescription: Prevalence of arterial thrombosis
Measure: Prevalence of arterial thrombosis Time: 19 yearsDescription: Prevalence of venous thrombosis
Measure: Prevalence of venous thrombosis Time: 19 yearsDescription: Maturation delay of the arteriovenous fistula
Measure: Maturation delay of the arteriovenous fistula Time: 19 yearsDescription: Percentage of thrombosis of the filter
Measure: Percentage of thrombosis of the filter Time: 19 yearsDescription: Lifespan of the catheter
Measure: Lifespan of the catheter Time: 19 yearsDescription: Lifespan of the fistula
Measure: Lifespan of the fistula Time: 19 yearsDescription: Existence of at least one of the following pro-thrombotic risk factors: smoking, active neoplasia, arterial hypertension.
Measure: Existence of thrombosis risk factors Time: 19 yearsDescription: Existence of an anticoagulant treatment Presence of an anticoagulant treatment by means of anti-vitamin K
Measure: Anticoagulant treatment Time: 19 yearsDescription: Existence of an antiplatelet treatment
Measure: Antiplatelet treatment Antiplatelet treatment Time: 19 yearsDescription: Existence of an antihypertensive treatment
Measure: Antihypertensive treatment Time: 19 yearsDescription: Existence of a treatment by means of statins
Measure: Statin treatment Time: 19 yearsDescription: Known versus unknown ethiology
Measure: Ethiology of the nephropathy (known/unknown) Time: 19 yearsDescription: Glomerular versus non-glomerular ethiology
Measure: Ethiology of the nephropathy (glomerular) Time: 19 yearsDescription: Age at dialysis entry
Measure: Age at dialysis entry Time: 19 yearsDescription: Catheter versus distal arteriovenous fistula versus proximal arteriovenous fistula
Measure: Vascular access Time: 19 yearsDescription: Hemodiafiltration versus conventional hemodialysis
Measure: Type of dialysis Time: 19 yearsDescription: With or without heparin
Measure: Type of per-dialytic anticoagulation Time: 19 yearsDescription: Brand of dialysis membrane
Measure: Brand of dialysis membrane Time: 19 yearsDescription: Urea change percentage
Measure: Urea change percentage Time: Last available result within 19 yearsDescription: Coagulation assessment
Measure: Activated partial thromboplastin time (aPTT) Time: Last available result within 19 yearsDescription: Hemoglobin count
Measure: Hemoglobin count Time: Last available result within 19 yearsDescription: Platelets count
Measure: Platelets count Time: Last available result within 19 yearsCohort
There is one SNP
Inclusion Criteria: - All patients undergoing dialysis within the CHU Brugmann Hospital Exclusion Criteria: - Mutation of factor V - Mutation G20210A of the prothrombin gene - Protein C deficiency - Protein S deficiency - Antithrombin III deficiency Inclusion Criteria: - All patients undergoing dialysis within the CHU Brugmann Hospital Exclusion Criteria: - Mutation of factor V - Mutation G20210A of the prothrombin gene - Protein C deficiency - Protein S deficiency - Antithrombin III deficiency Antiphospholipid Syndrome Antiphospholipid Syndrome null --- G20210A ---
Inclusion Criteria: - All patients undergoing dialysis within the CHU Brugmann Hospital Exclusion Criteria: - Mutation of factor V - Mutation G20210A of the prothrombin gene - Protein C deficiency - Protein S deficiency - Antithrombin III deficiency Inclusion Criteria: - All patients undergoing dialysis within the CHU Brugmann Hospital Exclusion Criteria: - Mutation of factor V - Mutation G20210A of the prothrombin gene - Protein C deficiency - Protein S deficiency - Antithrombin III deficiency Antiphospholipid Syndrome Antiphospholipid Syndrome null --- G20210A --- --- G20210A ---